Page 38 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

RESULTS:

X From the 1032 patients, 788 were included in the study. 66.5% of patients had used
previously MD and 33.5% patients UD delivery system.
Overall patient satisfaction:
X 78.3% of patients were satisfied or very satisfied with the MDDS.

X 82.2% of patients were satisfied enough to continue using the MDDS.

Primary criteria - Overall patient satisfaction use of Duokopt ®
3.6%

Very satisfied/Satisfied
18.1% Unsatisfied
Very unsatisfied

78.3%
78.3% are satisfied or
very satisfied with Duokopt ®
n=784
Parameters impacting patients satisfaction:
The type of the previously used delivery system and the dexterity issues impacted significantly
the patient satisfaction (p<0.05)
®
Q: Overall, are you satisfied with using Duokopt bottle?
Overall satisfaction of use:
X 75.5% of the patients declared being satisfied or very satisfied with the easiness of
opening the MDDS.

X 76.5% of patients reported that the MDDS was easy or very easy to handle.
X 70.2% of patients indicated that squeezing and obtaining a drop with the MDDS was
same as or easier compared to their previous glaucoma treatment.

X 73.5% of patients reported that it was easy or very easy to instill the drop with the MDDS.
Ophthalmologists’ satisfaction:
X 97.2% of the ophthalmologists were satisfied or very satisfied with the tested MDDS.
Compliance:

X 60.2% of patients report never forgot to use the delivery system.
X 20.2% of patients forgot to use the MDDS up to two times per month and 19.6% forgot
more than twice per monththeir treatment.

X A total of 39% of patients declared using their eye drops more regulary, since having
switched to the tested MDDS.
Concomitant use of tear substitutes:
X 57% of patients used tear substitutes, of those 31,4% stopped or decreased their conco-
mitant use since having switched to the tested MDDS.
IOP control:

X The mean IOP remained unchanged during the study IOP, reduction is still stable at 3
and 6 months of treatment with the tested MDDS.
Safety:
X 10 out of the 1032 patients (0,97%) who tested the MDDS reported 17 related, non-
serious adverse events. No adverse events were reported with the use of the bottle.

38